LINQ II Insertable Cardiac Monitor

The LINQ II Insertable Cardiac Monitor (ICM) system provides long-term subcutaneous ECG monitoring to detect and record cardiac arrhythmias automatically or via patient activation in adult and pediatric populations. Its methodology involves a biocompatible implanted sensor utilizing sapphire and titanium components for continuous ECG acquisition, with data processed and managed through associated software platforms like the newly validated CareLink SmartSync LINQ II Platform Application for arrhythmia analysis.

The LINQ II Insertable Cardiac Monitor (ICM), Model LNQ22, is a programmable device for continuous cardiac monitoring using subcutaneous ECG in adult and pediatric patients (two years and older). It is indicated for individuals at increased risk of cardiac arrhythmias or those experiencing transient symptoms like dizziness, palpitations, syncope, or chest pain suggestive of arrhythmia. The device aims to aid diagnosis by automatically detecting and recording cardiac arrhythmia episodes, while also allowing patients to manually initiate recordings during symptomatic events using associated applications like the MyCareLink Heart App or a Patient Assistant. Technologically, the LINQ II ICM continuously senses subcutaneous ECG, analyzing ventricular event timing to identify arrhythmias such as tachyarrhythmia, bradyarrhythmia, pause, and atrial fibrillation. The implant itself is constructed with a sapphire hybrid substrate, titanium foil electrodes coated with titanium nitride, and a titanium battery casing, powered by a 167 mAh lithium-based battery. This submission specifically addresses the LINQ II ICM's use with the new CareLink SmartSync LINQ II Platform Application (Model D00U027). While the core ICM hardware and its fundamental arrhythmia detection capabilities remain unchanged, design verification and validation testing for the new software application successfully demonstrated that it meets all specified design requirements and performance criteria, ensuring its suitability for integration into the LINQ II system.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific physiological parameters, beyond subcutaneous ECG, does the LINQ II ICM monitor, and how are these integrated into the arrhythmia detection algorithms mentioned in the device description?; How does the performance of the AccuRhythm AI ECG Classification System (Models ZA400, ZA410, ZA420), listed as an accessory, compare to previous classification algorithms or human expert interpretation in terms of sensitivity and specificity for the various arrhythmia types the LINQ II ICM detects?; What are the typical battery longevity expectations for the LINQ II ICM (167 mAh capacity) under various usage scenarios, considering continuous monitoring and varying rates of automatic and manual recordings?; Are there any specific patient populations or anatomical considerations (e.g., body mass index, amount of subcutaneous fat) where the subcutaneous ECG signal quality or the arrhythmia detection accuracy of the LINQ II ICM might be significantly affected?; What are the key usability improvements and data workflow efficiencies introduced by the new CareLink SmartSync LINQ II Platform Application (Model D00U027) for clinicians managing patients with LINQ II devices, compared to previous software interfaces?